Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Sells $94,800.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total transaction of $94,800.00. Following the completion of the transaction, the chief financial officer now directly owns 1,426,506 shares of the company’s stock, valued at approximately $9,015,517.92. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Michael Secora also recently made the following trade(s):

• On Tuesday, September 10th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00.
• On Tuesday, August 13th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.35, for a total transaction of $95,250.00.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $6.62 on Friday. The stock has a market cap of $1.57 billion, a PE ratio of -4.14 and a beta of 0.80. The company’s fifty day moving average is $6.69 and its 200 day moving average is $7.89. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.97 and a 52 week high of $15.74. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.38) EPS. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Analysts Set New Price Targets

RXRX has been the topic of several research reports. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC lowered their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Finally, Jefferies Financial Group lowered their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.40.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC grew its holdings in Recursion Pharmaceuticals by 24.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 25,182 shares of the company’s stock worth $166,000 after acquiring an additional 5,021 shares during the last quarter. San Luis Wealth Advisors LLC bought a new stake in Recursion Pharmaceuticals in the 3rd quarter worth $69,000. Green Alpha Advisors LLC grew its holdings in Recursion Pharmaceuticals by 2.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after acquiring an additional 1,800 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in Recursion Pharmaceuticals by 33.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company’s stock worth $458,000 after acquiring an additional 17,400 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in Recursion Pharmaceuticals by 249.0% in the 3rd quarter. SG Americas Securities LLC now owns 89,325 shares of the company’s stock worth $589,000 after acquiring an additional 63,727 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.